Abiomed (NASDAQ: ABMD) announced this week that it has acquired PreCardia and its catheter-based system to treat acute decompensated heart failure.
The financial terms of the deal were not disclosed in the June 1 announcement.
Abiomed officials say the deal complements the company’s product portfolio, expanding options for patients with acute decompensated heart failure.
The PreCardia system is meant to quickly reduce congestion in the venous system to improve overall cardiorenal function. The technology includes a balloon catheter and pump controller to address acute decompensated heart failure through the intermittent superior vena cava occlusion.
St. Paul, Minn.–based PreCardia won FDA breakthrough device designation for its system in June 2020.
“We look forward to advancing PreCardia’s technology through the regulatory process and expanding our relationship with heart failure specialists to help improve outcomes in early-stage acute decompensated heart failure patients, a new patient population for Abiomed,” Abiomed CEO Michael R. Minogue said in a news release.
Minogue added that the deal “aligns with Abiomed’s principles of leading in technology and innovation and putting patients first.”
